APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Non-invasive Insulin

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Non-invasive Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174017600327 December 2025199 pages

Choose your research edition.

Industry ResearchNon-invasive Insulin Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-invasive Insulin Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Non-invasive Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-invasive Insulin Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-invasive Insulin Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Non-invasive Insulin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Non-invasive Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-invasive Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-invasive Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Non-invasive Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Non-invasive Insulin include Sanofi, Novo Nordisk, Eli Lilly, Biocon, Zafgen, Verily Life Sciences, Senseonics, Oramed Pharmaceuticals and Medtronic, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-invasive Insulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-invasive Insulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-invasive Insulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-invasive Insulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-invasive Insulin Segment by Company

Sanofi

Novo Nordisk

Eli Lilly

Biocon

Zafgen

Verily Life Sciences

Senseonics

Oramed Pharmaceuticals

Medtronic

MannKind Corporation

Janssen Pharmaceuticals

Dance Biopharm

Bigfoot Biomedical

Adocia

Non-invasive Insulin Segment by Type

Pills

Sprays

Others

Non-invasive Insulin Segment by Application

Hospital Pharmacies

Online Pharmacies

Drug Stores

Non-invasive Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-invasive Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-invasive Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-invasive Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-invasive Insulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Non-invasive Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Non-invasive Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Non-invasive Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Non-invasive Insulin Industry Trends Table 2. Non-invasive Insulin Industry Drivers Table 3. Non-invasive Insulin Industry Opportunities and Challenges Table 4. Non-invasive Insulin Industry Restraints Table 5. Global Non-invasive Insulin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Non-invasive Insulin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Non-invasive Insulin Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Non-invasive Insulin Sales Market Share by Manufacturers Table 9. Global Non-invasive Insulin Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Non-invasive Insulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Non-invasive Insulin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Non-invasive Insulin Manufacturers, Product Type & Application Table 13. Global Non-invasive Insulin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-invasive Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pills Table 17. Major Manufacturers of Sprays Table 18. Major Manufacturers of Others Table 19. Global Non-invasive Insulin Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Non-invasive Insulin Sales by Type (2021-2026) & (K Units) Table 21. Global Non-invasive Insulin Sales by Type (2027-2032) & (K Units) Table 22. Global Non-invasive Insulin Sales Market Share by Type (2021-2026) Table 23. Global Non-invasive Insulin Sales Market Share by Type (2027-2032) Table 24. Global Non-invasive Insulin Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Non-invasive Insulin Revenue by Type (2021-2026) & (K Units) Table 26. Global Non-invasive Insulin Revenue by Type (2027-2032) & (K Units) Table 27. Global Non-invasive Insulin Revenue Market Share by Type (2021-2026) Table 28. Global Non-invasive Insulin Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacies Table 30. Major Manufacturers of Online Pharmacies Table 31. Major Manufacturers of Drug Stores Table 32. Global Non-invasive Insulin Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Non-invasive Insulin Sales by Application (2021-2026) & (K Units) Table 34. Global Non-invasive Insulin Sales by Application (2027-2032) & (K Units) Table 35. Global Non-invasive Insulin Sales Market Share by Application (2021-2026) Table 36. Global Non-invasive Insulin Sales Market Share by Application (2027-2032) Table 37. Global Non-invasive Insulin Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Non-invasive Insulin Revenue by Application (2021-2026) & (K Units) Table 39. Global Non-invasive Insulin Revenue by Application (2027-2032) & (K Units) Table 40. Global Non-invasive Insulin Revenue Market Share by Application (2021-2026) Table 41. Global Non-invasive Insulin Revenue Market Share by Application (2027-2032) Table 42. Global Non-invasive Insulin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Non-invasive Insulin Sales by Region (2021-2026) & (K Units) Table 44. Global Non-invasive Insulin Sales Market Share by Region (2021-2026) Table 45. Global Non-invasive Insulin Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Non-invasive Insulin Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 49. North America Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 50. Europe Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 52. Europe Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 59. Global Non-invasive Insulin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Non-invasive Insulin Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Non-invasive Insulin Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Non-invasive Insulin Revenue Market Share by Region (2021-2026) Table 63. Global Non-invasive Insulin Revenue Market Share by Region (2027-2032) Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sanofi Non-invasive Insulin Product Portfolio Table 68. Sanofi Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novo Nordisk Non-invasive Insulin Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Eli Lilly Company Information Table 75. Eli Lilly Business Overview Table 76. Eli Lilly Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eli Lilly Non-invasive Insulin Product Portfolio Table 78. Eli Lilly Recent Development Table 79. Biocon Company Information Table 80. Biocon Business Overview Table 81. Biocon Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Biocon Non-invasive Insulin Product Portfolio Table 83. Biocon Recent Development Table 84. Zafgen Company Information Table 85. Zafgen Business Overview Table 86. Zafgen Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Zafgen Non-invasive Insulin Product Portfolio Table 88. Zafgen Recent Development Table 89. Verily Life Sciences Company Information Table 90. Verily Life Sciences Business Overview Table 91. Verily Life Sciences Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Verily Life Sciences Non-invasive Insulin Product Portfolio Table 93. Verily Life Sciences Recent Development Table 94. Senseonics Company Information Table 95. Senseonics Business Overview Table 96. Senseonics Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Senseonics Non-invasive Insulin Product Portfolio Table 98. Senseonics Recent Development Table 99. Oramed Pharmaceuticals Company Information Table 100. Oramed Pharmaceuticals Business Overview Table 101. Oramed Pharmaceuticals Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Oramed Pharmaceuticals Non-invasive Insulin Product Portfolio Table 103. Oramed Pharmaceuticals Recent Development Table 104. Medtronic Company Information Table 105. Medtronic Business Overview Table 106. Medtronic Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Medtronic Non-invasive Insulin Product Portfolio Table 108. Medtronic Recent Development Table 109. MannKind Corporation Company Information Table 110. MannKind Corporation Business Overview Table 111. MannKind Corporation Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. MannKind Corporation Non-invasive Insulin Product Portfolio Table 113. MannKind Corporation Recent Development Table 114. Janssen Pharmaceuticals Company Information Table 115. Janssen Pharmaceuticals Business Overview Table 116. Janssen Pharmaceuticals Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Janssen Pharmaceuticals Non-invasive Insulin Product Portfolio Table 118. Janssen Pharmaceuticals Recent Development Table 119. Dance Biopharm Company Information Table 120. Dance Biopharm Business Overview Table 121. Dance Biopharm Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Dance Biopharm Non-invasive Insulin Product Portfolio Table 123. Dance Biopharm Recent Development Table 124. Bigfoot Biomedical Company Information Table 125. Bigfoot Biomedical Business Overview Table 126. Bigfoot Biomedical Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Bigfoot Biomedical Non-invasive Insulin Product Portfolio Table 128. Bigfoot Biomedical Recent Development Table 129. Adocia Company Information Table 130. Adocia Business Overview Table 131. Adocia Non-invasive Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Adocia Non-invasive Insulin Product Portfolio Table 133. Adocia Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Non-invasive Insulin Distributors List Table 137. Non-invasive Insulin Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Non-invasive Insulin Product Image Figure 2. Global Non-invasive Insulin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-invasive Insulin Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-invasive Insulin Sales (2021-2032) & (K Units) Figure 5. Global Non-invasive Insulin Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Non-invasive Insulin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pills Image Figure 9. Sprays Image Figure 10. Others Image Figure 11. Global Non-invasive Insulin Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Non-invasive Insulin Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Non-invasive Insulin Sales Market Share by Type (2021-2032) Figure 14. Global Non-invasive Insulin Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Non-invasive Insulin Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Non-invasive Insulin Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacies Image Figure 18. Online Pharmacies Image Figure 19. Drug Stores Image Figure 20. Global Non-invasive Insulin Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Non-invasive Insulin Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Non-invasive Insulin Sales Market Share by Application (2021-2032) Figure 23. Global Non-invasive Insulin Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Non-invasive Insulin Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Non-invasive Insulin Revenue Market Share by Application (2021-2032) Figure 26. North America Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 28. U.S. Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 33. Germany Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 40. China Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 48. Brazil Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Non-invasive Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Non-invasive Insulin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Non-invasive Insulin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Non-invasive Insulin Revenue (2021-2032) & (US$ Million) Figure 59. North America Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Non-invasive Insulin Revenue (2021-2032) & (US$ Million) Figure 61. Europe Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Non-invasive Insulin Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Non-invasive Insulin Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Non-invasive Insulin Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Non-invasive Insulin Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Pills
  • Sprays
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Drug Stores
Companies covered
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • Biocon
  • Zafgen
  • Verily Life Sciences
  • Senseonics
  • Oramed Pharmaceuticals
  • Medtronic
  • MannKind Corporation
  • Janssen Pharmaceuticals
  • Dance Biopharm
  • Bigfoot Biomedical
  • Adocia

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-invasive Insulin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-invasive Insulin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Non-invasive Insulin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Non-invasive Insulin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Non-invasive Insulin Market Dynamics
  1. 2.1 Non-invasive Insulin Industry Trends
  2. 2.2 Non-invasive Insulin Industry Drivers
  3. 2.3 Non-invasive Insulin Industry Opportunities and Challenges
  4. 2.4 Non-invasive Insulin Industry Restraints
3 Non-invasive Insulin Market by Manufacturers
  1. 3.1 Global Non-invasive Insulin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Non-invasive Insulin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Non-invasive Insulin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Non-invasive Insulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Non-invasive Insulin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Non-invasive Insulin Manufacturers, Product Type & Application
  7. 3.7 Global Non-invasive Insulin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Non-invasive Insulin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Non-invasive Insulin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Non-invasive Insulin Tier 1, Tier 2, and Tier 3
4 Non-invasive Insulin Market by Type
  1. 4.1 Non-invasive Insulin Type Introduction
  2. 4.1.1 Pills
  3. 4.1.2 Sprays
  4. 4.1.3 Others
  5. 4.2 Global Non-invasive Insulin Sales by Type
  6. 4.2.1 Global Non-invasive Insulin Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Non-invasive Insulin Sales by Type (2021-2032)
  8. 4.2.3 Global Non-invasive Insulin Sales Market Share by Type (2021-2032)
  9. 4.3 Global Non-invasive Insulin Revenue by Type
  10. 4.3.1 Global Non-invasive Insulin Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Non-invasive Insulin Revenue by Type (2021-2032)
  12. 4.3.3 Global Non-invasive Insulin Revenue Market Share by Type (2021-2032)
5 Non-invasive Insulin Market by Application
  1. 5.1 Non-invasive Insulin Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Drug Stores
  5. 5.2 Global Non-invasive Insulin Sales by Application
  6. 5.2.1 Global Non-invasive Insulin Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-invasive Insulin Sales by Application (2021-2032)
  8. 5.2.3 Global Non-invasive Insulin Sales Market Share by Application (2021-2032)
  9. 5.3 Global Non-invasive Insulin Revenue by Application
  10. 5.3.1 Global Non-invasive Insulin Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Non-invasive Insulin Revenue by Application (2021-2032)
  12. 5.3.3 Global Non-invasive Insulin Revenue Market Share by Application (2021-2032)
6 Global Non-invasive Insulin Sales by Region
  1. 6.1 Global Non-invasive Insulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-invasive Insulin Sales by Region (2021-2032)
  3. 6.2.1 Global Non-invasive Insulin Sales by Region (2021-2026)
  4. 6.2.2 Global Non-invasive Insulin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Non-invasive Insulin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Non-invasive Insulin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Non-invasive Insulin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Non-invasive Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Non-invasive Insulin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Non-invasive Insulin Revenue by Region
  1. 7.1 Global Non-invasive Insulin Revenue by Region
  2. 7.1.1 Global Non-invasive Insulin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Non-invasive Insulin Revenue by Region (2021-2026)
  4. 7.1.3 Global Non-invasive Insulin Revenue by Region (2027-2032)
  5. 7.1.4 Global Non-invasive Insulin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Non-invasive Insulin Revenue (2021-2032)
  8. 7.2.2 North America Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Non-invasive Insulin Revenue (2021-2032)
  11. 7.3.2 Europe Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Non-invasive Insulin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Non-invasive Insulin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Non-invasive Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Non-invasive Insulin Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Non-invasive Insulin Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Non-invasive Insulin Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Biocon
  20. 8.4.1 Biocon Company Information
  21. 8.4.2 Biocon Business Overview
  22. 8.4.3 Biocon Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biocon Non-invasive Insulin Product Portfolio
  24. 8.4.5 Biocon Recent Developments
  25. 8.5 Zafgen
  26. 8.5.1 Zafgen Company Information
  27. 8.5.2 Zafgen Business Overview
  28. 8.5.3 Zafgen Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zafgen Non-invasive Insulin Product Portfolio
  30. 8.5.5 Zafgen Recent Developments
  31. 8.6 Verily Life Sciences
  32. 8.6.1 Verily Life Sciences Company Information
  33. 8.6.2 Verily Life Sciences Business Overview
  34. 8.6.3 Verily Life Sciences Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Verily Life Sciences Non-invasive Insulin Product Portfolio
  36. 8.6.5 Verily Life Sciences Recent Developments
  37. 8.7 Senseonics
  38. 8.7.1 Senseonics Company Information
  39. 8.7.2 Senseonics Business Overview
  40. 8.7.3 Senseonics Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Senseonics Non-invasive Insulin Product Portfolio
  42. 8.7.5 Senseonics Recent Developments
  43. 8.8 Oramed Pharmaceuticals
  44. 8.8.1 Oramed Pharmaceuticals Company Information
  45. 8.8.2 Oramed Pharmaceuticals Business Overview
  46. 8.8.3 Oramed Pharmaceuticals Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Oramed Pharmaceuticals Non-invasive Insulin Product Portfolio
  48. 8.8.5 Oramed Pharmaceuticals Recent Developments
  49. 8.9 Medtronic
  50. 8.9.1 Medtronic Company Information
  51. 8.9.2 Medtronic Business Overview
  52. 8.9.3 Medtronic Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medtronic Non-invasive Insulin Product Portfolio
  54. 8.9.5 Medtronic Recent Developments
  55. 8.10 MannKind Corporation
  56. 8.10.1 MannKind Corporation Company Information
  57. 8.10.2 MannKind Corporation Business Overview
  58. 8.10.3 MannKind Corporation Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MannKind Corporation Non-invasive Insulin Product Portfolio
  60. 8.10.5 MannKind Corporation Recent Developments
  61. 8.11 Janssen Pharmaceuticals
  62. 8.11.1 Janssen Pharmaceuticals Company Information
  63. 8.11.2 Janssen Pharmaceuticals Business Overview
  64. 8.11.3 Janssen Pharmaceuticals Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Janssen Pharmaceuticals Non-invasive Insulin Product Portfolio
  66. 8.11.5 Janssen Pharmaceuticals Recent Developments
  67. 8.12 Dance Biopharm
  68. 8.12.1 Dance Biopharm Company Information
  69. 8.12.2 Dance Biopharm Business Overview
  70. 8.12.3 Dance Biopharm Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dance Biopharm Non-invasive Insulin Product Portfolio
  72. 8.12.5 Dance Biopharm Recent Developments
  73. 8.13 Bigfoot Biomedical
  74. 8.13.1 Bigfoot Biomedical Company Information
  75. 8.13.2 Bigfoot Biomedical Business Overview
  76. 8.13.3 Bigfoot Biomedical Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bigfoot Biomedical Non-invasive Insulin Product Portfolio
  78. 8.13.5 Bigfoot Biomedical Recent Developments
  79. 8.14 Adocia
  80. 8.14.1 Adocia Company Information
  81. 8.14.2 Adocia Business Overview
  82. 8.14.3 Adocia Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Adocia Non-invasive Insulin Product Portfolio
  84. 8.14.5 Adocia Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-invasive Insulin Value Chain Analysis
  2. 9.1.1 Non-invasive Insulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-invasive Insulin Production Mode & Process
  6. 9.2 Non-invasive Insulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-invasive Insulin Distributors
  9. 9.2.3 Non-invasive Insulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst